Phaseline

Companies › EyePoint Pharmaceuticals

EyePoint Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 4 Phase 3; Ophthalmology; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EYP-1901
VEGF inhibitor
–Phase 3Wet Age Related Macular Degeneration; Diabetic Macular EdemaAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06668064EYP-1901Phase 3Wet Age Related Macular DegenerationOphthalmologyAug 2027
NCT07449936EYP-1901Phase 3Diabetic Macular EdemaOphthalmologyOct 2027
NCT06683742EYP-1901Phase 3Wet Age Related Macular DegenerationOphthalmologyOct 2027
NCT07449923EYP-1901Phase 3Diabetic Macular EdemaOphthalmologyOct 2027

From the company's SEC filings

Cash and short-term investments of $180m on 2026-06-30; operating cash outflow about $290m a year; runway about 8 months at that burn, to Feb 2027; 0 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Kodiak Sciences SpyGlass Pharma AiViva BioPharma Santen Pharmaceutical Adverum Biotechnologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.